Clinical trial to relapse of itching after the stop of nalfurafine for chronic hepatitis C, or cirrhosis.

Clinical trial to relapse of itching after the stop of nalfurafine for chronic hepatitis C, or cirrhosis. - Clinical trial to relapse of itching after the stop of nalfurafine.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000023363

Enrollment

Registered

2016-07-27

Start date

2016-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic hepatitis C, or liver cirrhosis.

Interventions

Patients select whether nalfurafine should be orally sdministered for 4 weeks, or stopped.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Chronic hepatitis C, or cirrhosis. 2) 20 years or more at the entry of study. 3) After the pretreatment of nalfurafine for 4 weeks or more, the decrease of Visual Analogue Scale (VAS) was 50 mm or more, and improvement of itching was confirmed.

Exclusion criteria

Exclusion criteria: 1) Ineligible patients by judgement of family doctor. 2) Mental disorder 3) Chronic renal failures 4) Severe liver damage (Child Pugh; Grade C)

Design outcomes

Primary

Measure	Time frame
Ralapse rates of itching after the stop of treatment, or at 4 weeks of treatment contiunation.	—

Countries

Japan

Contacts

Public ContactNorio Akuta

Toranomon Hospital Hepatology

norioakuta@toranomon.gr.jp044-877-5111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026